消息公布后，礼来美股盘前一度涨逾1.5%，最终收涨0.62%。由于减肥药的高需求，截至收盘，今年迄今礼来公司股价已累涨近56%。US pharmaceutical giant Eli Lilly and Co. announced that Lucas Montarce, a senior financial expert within the company, has been appointed as the Chief Financial Officer, and the appointment is effective immediately. This personnel change comes at a critical moment as Eli Lilly is investing billions of dollars to expand production to meet the increasing demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound). Despite FDA approval, Eli Lilly still faces supply shortages.
On Monday, September 9th, Eastern Time, the pharmaceutical company in the United States announced the appointment of Lucas Montarce, a senior financial expert within the company, as the new CFO. This appointment takes effect immediately and was made several months after former CFO Anat Ashkenazi resigned and joined Alphabet, Google's parent company. $Eli Lilly and Co (LLY.US)$ After the news was announced, Eli Lilly's pre-market trading rose by more than 1.5%, and finally closed with a gain of 0.62%. Due to the high demand for weight loss drugs, as of the close of trading, Eli Lilly's stock price has risen nearly 56% this year. Some analysts predict that by the early 2030s, the global weight loss drug market could exceed $150 billion.
This executive change at Eli Lilly comes at a crucial time as the company is investing billions of dollars to expand its production capacity in response to the surging demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound).
On Monday, September 9th, Eastern Time, the pharmaceutical company in the United States announced the appointment of Lucas Montarce, a senior financial expert within the company, as the new CFO. This appointment takes effect immediately and was made several months after former CFO Anat Ashkenazi resigned and joined Alphabet, Google's parent company.
Since joining Eli Lilly in 2001, Lucas Montarce has had extensive financial management experience. He has served as the finance director in Eli Lilly's research laboratories and international division, and earlier this year, he held the position of President and General Manager for Eli Lilly's Spain, Portugal, and Greece region. In his new role, Montarce will serve as both Chief Financial Officer and Executive Vice President, with an annual base salary of $1 million and eligibility for a $1 million annual target bonus.
Despite Eli Lilly's drugs being approved by the US Food and Drug Administration (FDA), they still remain on the FDA's official drug shortage list and have spent most of their time on that list. This highlights the supply chain management and production capacity challenges in the weight loss drug industry. Currently, both Eli Lilly and Novo Nordisk are struggling to meet the enormous demand for their weight loss drugs. Eli Lilly has recently increased its production capacity and raised its annual sales forecast by $3 billion. In contrast, Novo Nordisk has fallen short of expectations in the most recent quarter.
Editor/Somer
